医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Food and Drug

AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo

AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo

バイオテクノロジーヘルスケア病院臨床試験製薬　 TimeLine: AVITA Medical Files Food and Drug IDE RECELL System Investigational Device Exemption

2020年06月02日

Astex Pharmaceuticals Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727 or oral C-DEC), for the Treatment of MDS and CMML

Astex Pharmaceuticals Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727 or oral C-DEC), for the Treatment of MDS and CMML

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: Administration Astex Pharmaceuticals Announces ASTX727 or oral C-DEC FDA Food and Drug

2020年02月12日